Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer. - Wikidata - awgldk - TriplyDB

Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.

Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.

http://www.wikidata.org/entity/Q33818578

about

Clarifying lysosomal storage diseases Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data Enhanced sialylation and in vivo efficacy of recombinant human α-galactosidase through in vitro glycosylation Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.Gene therapy for fabry disease: a review of the literature.Anderson-Fabry disease in heart failure

P2860

Q24620532-5A6A136C-E0D1-4F2B-8715-26F841F0D171 Q30578294-C164F056-0FD2-4FD0-A621-8E8B1548EB28 Q34049393-8248BE09-409B-4175-8240-4A52CDF8A366 Q34294988-F7296DAA-7BD8-4509-B37C-B090F50A1E92 Q35152240-E51D3E59-54F7-42DE-9263-B221DFC79AF0 Q38098070-4953C94D-8F45-4AE6-B659-7226276C37FF Q56807662-47A3AD5C-DE3B-4375-A3A4-32E257168880

P2860

Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.

http://www.wikidata.org/entity/Q33818578

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Characterization of Fabry mice ...... us 2/8-mediated gene transfer.

@ast

Characterization of Fabry mice ...... us 2/8-mediated gene transfer.

@en

type

label

Characterization of Fabry mice ...... us 2/8-mediated gene transfer.

@ast

Characterization of Fabry mice ...... us 2/8-mediated gene transfer.

@en

prefLabel

Characterization of Fabry mice ...... us 2/8-mediated gene transfer.

@ast

Characterization of Fabry mice ...... us 2/8-mediated gene transfer.

@en

P1433

Q33818578-76D0D2D1-DF27-4666-A037-17CE956EFD6D

P1476

Q33818578-B1FDF8CF-3522-41D9-9A4F-05191807BAC9

P2093

Q33818578-2AD7FCF6-6D93-4A36-99CD-8639EE4C6165

Q33818578-6B033D84-3CDA-4D30-887B-C75550463712

Q33818578-DB8F276D-BFFB-419A-AE57-352919068F41

P2860

Q33818578-0BC07EF2-05EF-439B-BF11-A0288AF685B4

Q33818578-15CA3D5C-721E-4891-8888-ECFD534544A8

Q33818578-19D4423B-FDFF-42B6-BEEE-3D34AF43FF1F

Q33818578-201BDEB0-CAEF-4366-8B6E-75696149CF9F

Q33818578-235F0A86-3CFC-4037-9298-D4D4ADE0D6A2

Q33818578-25C9697A-EFA2-4F25-B792-2E21C445F401

Q33818578-30CAE2F8-0B6D-41D3-A6AD-094655D35893

Q33818578-3BEC354C-1726-4BA2-BE52-D7008D787E47

Q33818578-3ECCE611-07A6-48A8-9E9C-FDB6D3DA1BAE

Q33818578-445D7C27-A640-496B-9B13-BBC1917BDFC8

P2888

Q33818578-A7DB7E6E-EB10-4064-9ADA-27ACCAC939D8

P304

Q33818578-EDF87D80-0AE1-4A91-B2E8-CD01A50B4986

P31

Q33818578-5A826689-0D31-44E1-91FC-3526A78C9A50

P356

Q33818578-74A6B215-0439-4921-B592-E5219C79231C

P478

Q33818578-326F3861-44A6-4F67-AF6B-01F7040B19FA

P50

Q33818578-8A8408ED-3EDC-460A-A7D2-3C3B3E7858AE

P577

Q33818578-532E8330-ECC5-47B4-948E-FD3F08FB1E93

P5875

Q33818578-CD390195-CF37-4789-867C-D6F1E5A28285

P698

Q33818578-FDDA1501-404E-4015-B64C-C8D3F7535199

P932

Q33818578-B0F5DE38-CB2B-4E72-A434-4E7BE5B9AE63

P356

1423-0127-17-26

P1433

Journal of Biomedical Science

P1476

Characterization of Fabry mice ...... us 2/8-mediated gene transfer.

@en

P2093

Hae-Young Park

http://www.w3.org/2001/XMLSchema#string

Jin-Ok Choi

http://www.w3.org/2001/XMLSchema#string

Mi Hee Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.

alpha-Galactosidase A deficient mice: a model of Fabry disease

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.

Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

P2888

1423-0127-17-26

P304

26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1423-0127-17-26

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43181018

http://www.w3.org/2001/XMLSchema#string

P698

20398385

http://www.w3.org/2001/XMLSchema#string

P932

2861641

http://www.w3.org/2001/XMLSchema#string